Literature DB >> 7751411

Pharmacokinetics and bioavailability of flucloxacillin in elderly hospitalized patients.

J Gath1, B Charles, J Sampson, B Smithurst.   

Abstract

The pharmacokinetics and oral bioavailability of flucloxacillin were studied in five female and two male patients (age 68-87 yr) who had been hospitalized for orthopedic surgeries. A single dose of intravenous or oral flucloxacillin sodium (500 mg) was administered in random order on different occasions separated by at least 2 days. Blood and urine samples were taken up to 24 hours after drug administration and levels of flucloxacillin and 5-hydroxymethylflucloxacillin (5-HMF), a major metabolite, were measured by high-performance liquid chromatography. Flucloxacillin elimination, but not oral absorption, was reduced in the elderly, compared with data from young healthy subjects reported elsewhere. Total clearance, renal clearance, and volume of distribution were 0.083 +/- 0.013 L/kg/hr, 0.038 +/- 0.01 L/kg/hr, and 0.184 +/- 0.034 L/kg, respectively. Regression of flucloxacillin renal clearance (Clr) on estimated creatine clearance (CLcr) gave the relationship: Clr = 0.755 (CLcr) + 10.6 (r = 0.91; P = 0.004). Terminal half-lives for flucloxacillin and 5-HMF were 2.21 +/- 0.51 hr and 3.0 +/- 0.75 hr, respectively after intravenous administration. Flucloxacillin was absorbed rapidly after oral administration with a mean absorption time of 0.95 +/- 0.34 hr, and time to reach peak concentration of 1.20 +/- 0.29 hr. The absolute bioavailability of flucloxacillin from capsules was 54.4 +/- 18.8%.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7751411     DOI: 10.1002/j.1552-4604.1995.tb04742.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  5 in total

Review 1.  [Antibiotic stewardship and Staphylococcus aureus Bacteremia].

Authors:  S Weis; A Kimmig; S Hagel; M W Pletz
Journal:  Med Klin Intensivmed Notfmed       Date:  2017-04-04       Impact factor: 0.840

2.  Inhibition of flucloxacillin tubular renal secretion by piperacillin.

Authors:  Cornelia B Landersdorfer; Carl M J Kirkpatrick; Martina Kinzig; Jürgen B Bulitta; Ulrike Holzgrabe; Fritz Sörgel
Journal:  Br J Clin Pharmacol       Date:  2008-11       Impact factor: 4.335

3.  Pharmacodynamics of Flucloxacillin in a Neutropenic Murine Thigh Infection Model: A Piece of the Puzzle towards Evidence-Based Dosing.

Authors:  Eveline E Roelofsen; Brenda C M de Winter; Heleen van der Spek; Susan Snijders; Birgit C P Koch; Sanne van den Berg; Anouk E Muller
Journal:  Antibiotics (Basel)       Date:  2022-08-03

4.  In healthy volunteers, taking flucloxacillin with food does not compromise effective plasma concentrations in most circumstances.

Authors:  Sharon J Gardiner; Philip G Drennan; Ronald Begg; Mei Zhang; Jared K Green; Heather L Isenman; Richard J Everts; Stephen T Chambers; Evan J Begg
Journal:  PLoS One       Date:  2018-07-12       Impact factor: 3.240

5.  Characterization of kinetics of human cytochrome P450s involved in bioactivation of flucloxacillin: inhibition of CYP3A-catalysed hydroxylation by sulfaphenazole.

Authors:  Stefan J Dekker; Floor Dohmen; Nico P E Vermeulen; Jan N M Commandeur
Journal:  Br J Pharmacol       Date:  2018-12-26       Impact factor: 8.739

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.